IDEXX Laboratories, Inc. (IDXX) Stock Price & How to Invest

Last updated November 2026

Short answer

IDEXX Laboratories is the dominant veterinary diagnostics franchise, and it runs a razor and blade model: analyzers get placed inside vet clinics, then Catalyst slides, SediVue cartridges and reference lab panels bill for years afterward. Recurring companion animal diagnostics are roughly ~80% of company revenue, which is why the shares still carry a ~40x trailing multiple (about ~$564 on October 16, 2026, down ~16% year to date) even as US clinic visits shrink.

IDXX stock price

As of 2026-11-16, IDEXX Laboratories, Inc. (IDXX) last closed at $700.65, up 4.7% over the past year. Over the past 52 weeks it has traded between $504.70 and $766.68.

IDXX last close
$700.65
1 day
-0.51%
1 month
+25.04%
1 year
+4.73%
52-week range
$504.70 to $766.68
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or IDEXX Laboratories, Inc.'s investor relations page. Walnut is informational, not investment advice.

IDXX key stats

At $700.65 on November 16, 2026, IDEXX Laboratories, Inc. (IDXX) has a market cap of $55.2B and a P/E of 47.2 on trailing earnings (41.5 on forward earnings). It next reports earnings around February 1, 2027 (estimated).

Market cap
$55.2B
P/E (trailing)
47.2
P/E (forward)
41.5
EPS (trailing 12 months)
$14.84
Price to book
29.5
Beta
1.54
Next earnings
around February 1, 2027 (estimated)

Market cap, P/E and yield are measured at the $700.65 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with IDEXX Laboratories, Inc. (IDXX)?

The last two weeks for IDEXX Laboratories, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • IDXX closed at $700.65 on November 16, 2026, down 0.8% over the past five trading days (from $706.65).
  • IDEXX Laboratories, Inc. next reports quarterly results around February 1, 2027 (estimated).
  • On November 3, 2026, Morgan Stanley raised its target to $810.00 from $805.00 (Overweight).
  • On November 3, 2026, UBS raised its target to $700.00 from $627.00 (Neutral).

IDEXX Laboratories, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

IDEXX Laboratories, Inc. (IDXX) latest quarter

IDEXX Laboratories reported revenue of $1.2 billion for Q3 2026, up 10% from a year earlier (IDEXX Laboratories, Nov 2, 2026).

Revenue
$1.2 billion
up 10% from a year earlier
Diluted EPS
$4.01
up 18% from a year earlier
Companion Animal Group (CAG)
$1.1 billion
up 10% from a year earlier

Source: IDEXX Laboratories Q3 2026 results, Nov 2, 2026. Full earnings breakdown

What does IDEXX Laboratories, Inc. (IDXX) do?

IDEXX Laboratories (NASDAQ: IDXX) sells diagnostics to veterinarians. Its Companion Animal Group, roughly ~92% of revenue, places in clinic analyzers (Catalyst, ProCyte, SediVue and the newer inVue Dx) into practices and then sells the consumables those instruments burn through, while a global reference laboratory network runs the panels clinics send out. Practice management software and digital imaging (ezyVet, Cornerstone, ImageVue) sit alongside the diagnostics and pull more testing through the same customers. Two smaller segments round out the business: Water, which tests drinking water for coliform bacteria, and Livestock, Poultry and Dairy. The company is headquartered in Westbrook, Maine, employs about ~11,000 people, and sells into more than 175 countries.

The economics explain the multiple. CAG Diagnostics recurring revenue reached ~$975 million in the June 2026 quarter, about ~80% of total company revenue, growing ~11% as reported while capital instrument sales fell ~20%. That inversion is the model working as designed, because hardware placements are the cost of acquiring an annuity rather than the profit. What complicates the story is the denominator: US same store clinical visits fell ~1.3% in the quarter, with wellness visits down more than ~3%, so growth now comes from more testing per visit, net price and international expansion rather than more animals through the door. Investors have de rated the stock hard on that point: it closed at roughly ~$564 on October 16, 2026, down ~16% year to date and ~12% over twelve months, against a 52 week high near ~$770, even after a second quarter beat and a raised full year outlook. A bounce of about ~10% over the past month has lifted it off a 52 week low near ~$501.

The newest strategic move is software. On September 30, 2026 IDEXX acquired CoVetAI, a veterinary AI platform, adding an AI tool to the practice software suite with the stated aim of pulling more diagnostic orders through the clinics that use it. Third quarter results arrive on November 2, 2026, with consensus near ~$3.70 of EPS on ~$1.19 billion of revenue.

What's driving IDEXX Laboratories, Inc. (IDXX)?

1. The CAG Diagnostics recurring annuity

CAG Diagnostics recurring revenue was ~$975 million in Q2 2026, up ~11% as reported and ~10% organic, and it carries the bulk of company gross profit. IDEXX VetLab consumables grew ~15% and reference laboratory services ~11%, both driven by testing volume rather than price alone. The soft spot inside that line is rapid assay products, up only ~1% as the Catalyst pancreatic lipase test pulls testing onto other modalities.

2. inVue Dx and the premium installed base

The inVue Dx cellular analyzer passed ~9,000 installed instruments after more than ~1,600 placements in the June quarter, and the global premium instrument installed base grew ~11%. Each placement depresses reported capital instrument revenue in the year it lands, which is most of why that line fell ~20%, while seeding consumable demand for years. IDEXX extended the platform again in August 2026 with a dual species point of care NT proBNP cardiac test.

3. Utilization offsetting flat visit volumes

US same store clinical visits declined ~1.3% in Q2 2026, yet US CAG Diagnostics recurring revenue still grew ~9.7%. The gap is diagnostic utilization: more panels per visit, an ageing pet population that needs more screening, and net price realization. At its August 2026 investor day the company restated long term targets of more than ~10% organic revenue growth, ~50 to ~100 basis points of annual margin expansion and roughly ~15% average EPS growth, against a stated ~$45 billion global companion animal testing opportunity.

4. Margin expansion and share repurchase

Second quarter gross margin reached ~64.0% and operating margin ~35.0%, each up about ~140 basis points year over year on volume leverage and productivity work. Full year guidance now calls for an operating margin of ~32.3% to ~32.5% and EPS of ~$14.69 to ~$14.94. Average share count is being reduced ~1.5% to ~2% annually, so buybacks contribute a couple of points of the reported EPS growth on top of operations. The trailing free cash flow figure Yahoo Finance reports is ~$909M against ~$1.37B of operating cash flow, so the pace of buybacks in the second half is worth watching against the first half's ~$700M.

5. Software and AI as a testing funnel

The September 30, 2026 purchase of CoVetAI, a veterinary AI platform, extends a strategy that began with ezyVet and Cornerstone: own the software the clinic works in, and make ordering an IDEXX panel the path of least resistance. Terms were not material enough to change guidance. At a Morgan Stanley conference in September management again reaffirmed the long term growth targets and pointed to cancer testing as a next diagnostic menu expansion.

What are the risks to IDEXX Laboratories, Inc. (IDXX)?

Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall. Wellness visits, down more than ~3%, sit at the discretionary end of veterinary spending and track consumer pressure and muted puppy adoption directly. Competition is intensifying from Mars owned Antech, which absorbed Heska and can now bundle in clinic analyzers with a national laboratory network the way IDEXX does, and from Zoetis in point of care instruments. Roughly ~23% of revenue is non US, so currency both flattered first half reported growth and now costs an estimated ~$15 million against the full year outlook. Leverage is not the concern, at about ~$1.1 billion of debt against ~$197 million of cash and ~$1.6 billion of EBITDA, but the ~27% drawdown from the 52 week high is a reminder of how fast this multiple reprices when the volume narrative wobbles.

What is the IDEXX Laboratories, Inc. (IDXX) forecast?

12 analysts publish price targets on IDXX, averaging $717.17 as of November 2026, or +2.4% against the $700.65 share price on November 16, 2026. The published targets run from $470.00 to $810.00, a moderate spread, and the ratings split 9 buy, 4 hold, 1 sell. Over the last six months there have been 4 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full IDXX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is IDXX a buy or a sell?

We give no verdict on IDEXX Laboratories, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The CAG Diagnostics recurring annuity. CAG Diagnostics recurring revenue was ~$975 million in Q2 2026, up ~11% as reported and ~10% organic, and it carries the bulk of company gross profit. The most optimistic published target, $810.00, assumes this works close to its best case.

The case against. Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall. The most pessimistic target, $470.00, is roughly what IDXX is worth if this bites instead.

Read the full bull and bear case on IDXX, including what would have to change to break either one. Walnut is not an investment adviser.

Has IDEXX Laboratories, Inc. (IDXX) split its stock?

No. IDEXX Laboratories, Inc. (IDXX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is IDEXX Laboratories, Inc. (IDXX) valued?

Market cap, P/E and dividend yield at today's price are in the IDXX key stats above. The business figures below come from IDEXX Laboratories, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$4.55B; Q2 2026 revenue up ~9.7% year over year
  • CAG Diagnostics recurring revenue (Q2 2026): ~$975M, up ~11%, about ~80% of total revenue
  • Margins (TTM): Gross ~62.5%, operating ~35.0%, net ~25.0%
  • Dividend: None; capital returned through buybacks
  • Next earnings: November 2, 2026; consensus EPS ~$3.70 on ~$1.19B revenue

As of October 2026: At roughly ~$564 a share and a market cap near ~$44.5B, IDEXX trades at about ~40x trailing earnings and ~34x the ~$16.73 analysts expect for 2027, and it pays no dividend. That is still a premium to the broader medical device group, though well below the multiples of 45x and above the stock carried through much of the past five years; the shares are down ~16% in 2026 and sit between a 52 week low of ~$501 and a high of ~$770. The twelve analysts Yahoo Finance tracks carry a mean target near ~$701, though JPMorgan trimmed its target to $750 from $775 on October 16.

Which ETFs hold IDEXX Laboratories, Inc. (IDXX)?

If you want IDXX exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in IDXXExpense ratio
FIWFirst Trust Water ETF3.97%0.53%
PHOInvesco Water Resources ETF6.89%0.59%
PIOInvesco Global Water ETF3.87%0.75%

Who competes with IDEXX Laboratories, Inc. (IDXX)?

Veterinary diagnostics

Mars owned Antech Diagnostics is the closest full line rival, having combined the former VCA reference laboratory network with Heska's in clinic analyzers, so it can run the same place the instrument then sell the consumable structure. Zoetis competes through its Vetscan point of care line and a growing laboratory footprint. Narrower challengers such as Zomedica and Fujifilm VET contest individual instrument categories rather than the whole test menu.

Veterinary practice software and imaging

IDEXX's ezyVet, Cornerstone and Neo systems compete with Covetrus (AVImark, Impromed), Vetspire, Shepherd and Digitail. Software matters less as a profit pool than as distribution, since the practice management system shapes which laboratory a clinic routes work to and how easily test results flow back into the record.

Water, livestock and dairy testing

The Water segment's Colilert products face Hach (Danaher), Thermo Fisher and bioMerieux in microbiological water testing, while the Livestock, Poultry and Dairy business competes with Zoetis, Thermo Fisher and Innovative Diagnostics. These two segments are under ~8% of revenue combined, but Water carries a ~74% gross margin and grew ~15% in the second quarter.

What stocks are similar to IDEXX Laboratories, Inc. (IDXX)?

Other names that sit close to IDXX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in IDEXX Laboratories, Inc. (IDXX)

There are three common ways to get IDXX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FIW, PHO, PIO), which spreads the position across many companies. Or build it into a focused thematic portfolio, so IDXX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where IDXX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on IDEXX Laboratories, Inc. (IDXX)

IDEXX is a high quality annuity on pet testing, and the live argument is whether ~10% recurring growth off a declining visit base justifies ~34x forward earnings, with the next test coming in the November 2, 2026 third quarter report.

More on IDEXX Laboratories, Inc. (IDXX)

Whether IDXX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IDXX a buy or a sell?, and where the stock could go from here in the IDXX stock forecast.

For income investors, whether IDXX pays a dividend and how the payout looks is covered in does IDXX pay a dividend? And to weigh IDXX against a peer, read the full side-by-side comparisons: IDXX vs ZTS and IDXX vs VET.

Wondering how IDXX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about IDEXX Laboratories, Inc.

Ask Walnut's AI anything about IDXX and see how it fits what you own.

FAQ

What does IDEXX Laboratories do?

+

IDEXX sells diagnostics to veterinary practices. It places blood chemistry, hematology and urinalysis analyzers inside clinics, sells the consumables those instruments use, and runs a global reference laboratory network for tests clinics send out. Smaller Water and Livestock, Poultry and Dairy segments test drinking water and farm animals. Companion animal work is roughly ~92% of revenue.

What is IDEXX's razor and blade model?

+

The analyzer is the razor and the test consumable is the blade. IDEXX places Catalyst, ProCyte, SediVue and inVue Dx instruments into practices at modest instrument revenue, then earns for years on slides, cartridges and reagents. Capital instrument sales fell ~20% in Q2 2026 while the recurring consumable and laboratory revenue they generate grew ~11%, which is the intended shape.

How much of IDEXX's revenue is recurring?

+

CAG Diagnostics recurring revenue was ~$975 million of ~$1.22 billion in total Q2 2026 revenue, about ~80%. Add recurring veterinary software revenue of ~$76 million and the share of the quarter that repeats rises to roughly ~86%. Capital instrument sales were only ~$47 million, or about ~4% of the quarter.

Are US veterinary clinic visits declining?

+

Yes. US same store clinical visits fell about ~1.3% in the June 2026 quarter, and wellness visits specifically were down more than ~3%, attributed to consumer pressure and subdued puppy adoption. An ageing pet population partly offsets that, since older animals get screened more often. US CAG Diagnostics recurring revenue still grew ~9.7% despite the visit decline.

How fast is IDEXX growing, and what is 2026 guidance?

+

Second quarter revenue rose ~9.7% as reported and ~9.0% organic to ~$1.22 billion, with EPS of ~$4.27, up ~18%. Full year 2026 guidance was narrowed to revenue of ~$4.70B to ~$4.75B, operating margin of ~32.3% to ~32.5% and EPS of ~$14.69 to ~$14.94. Long term targets restated in August 2026 call for more than ~10% organic growth and roughly ~15% average EPS growth.

What is IDEXX inVue Dx?

+

inVue Dx is a point of care cellular analyzer that lets a clinic run cytology and blood morphology in house rather than shipping samples out. The installed base passed ~9,000 units after more than ~1,600 placements in the June quarter. Its strategic value is the consumable and utilization pull it creates, not the instrument revenue itself, which is why heavy placement years depress the capital line.

Does IDEXX pay a dividend?

+

No. IDEXX returns capital entirely through share repurchase, cutting average shares outstanding by a guided ~1.5% to ~2% in 2026. Treasury stock rose roughly ~$700 million in the first half of the year. With free cash flow guided at ~90% to ~100% of net income, buyback capacity is comfortable at current leverage of about ~0.5x net debt to adjusted EBITDA.

Why is IDXX stock down in 2026?

+

As of October 16, 2026 the shares closed near ~$564, down ~16% year to date and ~12% over a year, and about ~27% below the 52 week high of ~$770, despite a Q2 beat and raised guidance. The de rating tracks the market's concern about US clinic visit declines and whether utilization gains can keep covering them indefinitely. A stock priced for durable double digit compounding is sensitive to any evidence the volume base is shrinking, so the multiple has compressed faster than the estimates. The stock did recover ~10% in the month before mid October.

How did IDEXX do in its latest quarter?

+

In the June 2026 quarter IDEXX reported revenue of ~$1.22 billion, up ~9.7%, and EPS of ~$4.27 against a consensus near ~$3.93, its fourth straight beat. Net income was ~$338 million versus ~$278 million in the March quarter. CAG Diagnostics recurring revenue grew ~11% and management narrowed full year EPS guidance to ~$14.69 to ~$14.94.

When does IDEXX report third quarter 2026 earnings?

+

IDEXX reports third quarter 2026 results on November 2, 2026. Analysts expect EPS near ~$3.70 on revenue of ~$1.19 billion, roughly ~9% growth. Full year 2026 consensus sits at ~$14.83 of EPS on ~$4.72 billion of revenue, within the company's own guidance range.

What is CoVetAI and why did IDEXX buy it?

+

CoVetAI is a veterinary AI platform that IDEXX acquired on September 30, 2026 from the Chicago Pacific Founders Pet Fund. It fits the company's software layer alongside ezyVet and Cornerstone. The reasoning is distribution: tools that sit inside a clinic's daily workflow shape which tests get ordered and which laboratory receives them.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with IDEXX Laboratories, Inc.'s investor relations page or your broker before making investment decisions.